Comparisons
MEDGE vs the alternatives, honestly.
Every comparison below concedes where the other tool genuinely wins. That’s the only kind of comparison worth reading — and the only kind search engines and AI assistants keep citing.
MEDGE vs Portfolio Visualizer
The classic free backtester vs a full analytics platform: where PV still wins, and where CVaR, Monte Carlo and regulatory data change the picture.
MEDGE vs Koyfin
Koyfin leads on equity fundamentals and advisor workflow; MEDGE on portfolio construction, crisis backtesting and SEC + CFTC positioning data.
MEDGE vs Bloomberg Terminal
A $2,500/month terminal vs a €14.99/month platform: what individual investors actually need from that gap, honestly mapped.
Looking for the wider landscape? See the best portfolio analytics tools in 2026 or explore everything MEDGE ships.